Ramon Alemany leads the Cancer Virotherapy Group at the Catalan Institute of Oncology (ICO) and the Institute of Biomedical Research of Bellvitge (IDIBELL). After a postdoctoral experience starting in 1993 in MD Anderson Cancer Center, Baxter Healthcare, and the University of Alabama at Birmingham, he came back to Spain in 2001 to start his research group on oncolytic adenoviruses to treat cancer. In this field he has published 110 papers and 14 patents. In 2009 he co-founded VCN Biosciences as a spin-off company. Amongst his honors are serving as an editor in journals such as Human Gene Therapy, Cancer Gene Therapy, Nanomedicine, and Molecular Therapy-Oncolytics, as a consultant in Selective Genetics, ORCA Theraputics, DNAtrix, Oncolytics Biotech, TILT Biotherapeutics, and Sagetis Biotech, and as President of the Spanish Society of Gene and Cell Therapy (SETGyC).